ReShape Lifesciences Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Paul Hickey

Chief Executive Officer (CEO)

US$506.4k

Compensación total

Porcentaje del salario del CEO	73.7%
Permanencia del CEO	2.3yrs
Participación del CEO	n/a
Permanencia media de la dirección	2.3yrs
Promedio de permanencia en la Junta Directiva	6.4yrs

Actualizaciones recientes de la dirección

Recent updates

It's A Story Of Risk Vs Reward With ReShape Lifesciences Inc. (NASDAQ:RSLS)

Apr 18

ReShape wins FDA clearance for device used in weight loss surgery

Aug 10

Analysts Have Lowered Expectations For ReShape Lifesciences Inc. (NASDAQ:RSLS) After Its Latest Results

Mar 31

Health Check: How Prudently Does ReShape Lifesciences (NASDAQ:RSLS) Use Debt?

Dec 09

Does ReShape Lifesciences (NASDAQ:RSLS) Have A Healthy Balance Sheet?

Aug 24

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Paul Hickey en comparación con los beneficios de ReShape Lifesciences?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-US$9m
Mar 31 2024	n/a	n/a	-US$11m
Dec 31 2023	US$506k	US$373k	-US$11m
Sep 30 2023	n/a	n/a	-US$26m
Jun 30 2023	n/a	n/a	-US$35m
Mar 31 2023	n/a	n/a	-US$41m
Dec 31 2022	US$158k	US$133k	-US$46m

Compensación vs. Mercado: La compensación total ($USD506.42K) de Paul está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD653.78K).

Compensación vs. Ingresos: La compensación de Paul ha aumentado mientras la empresa no es rentable.

CEO

Paul Hickey (59 yo)

2.3yrs

Permanencia

US$506,416

Compensación

Mr. Paul F. Hickey is Chief Executive Officer, President and Director at ReShape Lifesciences Inc. from August 15, 2022. He served as Senior Vice President of Marketing and Reimbursement at EnteroMedics In...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Dan Gladney	Executive Chair	9yrs	US$129.50k	0.0028% $ 82.2
Paul Hickey	CEO, President & Director	2.3yrs	US$506.42k	sin datos
Thomas Stankovich	Senior VP & CFO	5.1yrs	US$307.12k	0.078% $ 2.3k
Mark Knudson	Co-Founder and Special Advisor to the CEO	no data	US$746.85k	sin datos
Katherine Tweden	Co-Founder	no data	US$768.09k	sin datos
Al Diaz	Vice President of Operations and R&D	3.3yrs	sin datos	sin datos
Dov Gal	VP of Regulatory Clinical Quality & Compliance Officer	no data	sin datos	sin datos
Jody Dahlman	Director of Communications	no data	sin datos	sin datos
Naqeeb Ansari	Senior Vice President of Global Commercial Operations	2.2yrs	US$1.16m	sin datos

2.3yrs

Permanencia media

63yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de RSLS se considera experimentado (2.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Dan Gladney	Executive Chair	9yrs	US$129.50k	0.0028% $ 82.2
Paul Hickey	CEO, President & Director	2.3yrs	US$506.42k	sin datos
Ardaeviraf Minocherhomjee	Independent Director	6.3yrs	US$52.50k	sin datos
Gary Blackford	Independent Lead Director	8.3yrs	US$77.00k	sin datos
Philip Schauer	Member of Scientific Advisory Board	6.4yrs	sin datos	sin datos
Caroline Apovian	Member of Scientific Advisory Board	1.7yrs	sin datos	sin datos
Scott Shikora	Member of Scientific Advisory Board	6.4yrs	US$892.19k	sin datos
Lori McDougal	Independent Director	9.3yrs	US$57.50k	sin datos
Jaime Ponce	Member of Scientific Advisory Board	6.4yrs	sin datos	sin datos
John Morton	Member of Scientific Advisory Board	6.4yrs	sin datos	sin datos
Natan Zundel	Member of Scientific Advisory Board	6.4yrs	sin datos	sin datos
Michael Baptista	Member of Scientific Advisory Board	1.7yrs	sin datos	sin datos

6.4yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: La junta directiva de RSLS se considera experimentada (6.4 años de antigüedad promedio).

ReShape Lifesciences Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

ReShape Lifesciences Inc., Annual General Meeting, Feb 23, 2024

ReShape Lifesciences Inc., Annual General Meeting, Dec 14, 2022

Reshape Lifesciences Inc. Appoints Nick Ansari, as Senior Vice President of Global Commercial Operations

Insufficient new directors

ReShape Lifesciences Appoints Paul F. Hickey as Chief Executive Officer, Effective August 15, 2022

High number of new directors

Recent updates

ReShape Lifesciences Inc. announced that it expects to receive $0.833333 million in funding

Second quarter 2024 earnings released: US$0.063 loss per share (vs US$1.08 loss in 2Q 2023)

ReShape Lifesciences Inc. to Report Q2, 2024 Results on Aug 14, 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

ReShape Lifesciences Inc. to Report Q1, 2024 Results on May 15, 2024

The Nasdaq Stock Market Determines ReShape Lifesciences Eligible for an Additional 180 Calendar Period, or Until October 7, 2024, to Regain Compliance with Minimum Bid Price Requirement

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

ReShape Lifesciences Receives Notice of Allowance for Additional U.S. Patent Related to Intragastric Balloon System

Reshape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band 2.0 Flex

ReShape Lifesciences Inc., Annual General Meeting, Feb 23, 2024

Consensus EPS estimates upgraded to US$3.84 loss, revenue downgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

ReShape Lifesciences Inc. to Report Q3, 2023 Results on Nov 08, 2023

ReShape Lifesciences Receives Non-Compliance Notice From Nasdaq

ReShape Lifesciences Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation Device

Consensus revenue estimates decrease by 23%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

ReShape Lifesciences Inc. to Report Q2, 2023 Results on Aug 07, 2023

ReShape Lifesciences Inc. Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation(TM) Device at the ASMBS 2023 Annual Meeting

ReShape Lifesciences Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0

Consensus EPS estimates upgraded to US$5.85 loss, revenue downgraded

ReShape Lifesciences Inc. to Report Q1, 2023 Results on May 15, 2023

Consensus EPS estimates upgraded to US$16.50 loss

Full year 2022 earnings: EPS misses analyst expectations

It's A Story Of Risk Vs Reward With ReShape Lifesciences Inc. (NASDAQ:RSLS)

ReShape Lifesciences Inc. has completed a Composite Units Offering in the amount of $10.2 million.

ReShape Lifesciences Inc. has completed a Composite Units Offering in the amount of $10.2 million.

Consensus revenue estimates fall by 16%

ReShape Lifesciences Inc. Provides Revenue Guidance

Price target decreased to US$1.03

Third quarter 2022 earnings released: US$0.60 loss per share (vs US$1.48 loss in 3Q 2021)

ReShape Lifesciences Inc., Annual General Meeting, Dec 14, 2022

ReShape Lifesciences Inc. to Report Q3, 2022 Results on Nov 14, 2022

Reshape Lifesciences™ Announces That the ASMBS and IFSO Have Issued Updated Guidelines on Indications for Metabolic and Bariatric Surgery, Including the Lap-Band®

ReShape Lifesciences Announces Release of Positive Consensus Statement on Lap-Band Use and Lap-Band Aftercare Management by American Society of Metabolic and Bariatric Surgery

Reshape Lifesciences Inc. Appoints Nick Ansari, as Senior Vice President of Global Commercial Operations

ReShape Lifesciences Inc. announced delayed 10-Q filing

Price target decreased to US$3.08

Insufficient new directors

Reshape Lifesciences™ Receives FDA 510(K) Clearance for the Gibi Hd™ Calibration Tubes for Use in Gastric and Bariatric Procedures

ReShape wins FDA clearance for device used in weight loss surgery

ReShape Lifesciences Appoints Paul F. Hickey as Chief Executive Officer, Effective August 15, 2022

ReShape Lifesciences Receives Non-Compliance Notice from Nasdaq

ReShape Lifesciences Inc. to Report Q1, 2022 Results on May 23, 2022

ReShape Lifesciences Inc. announced delayed 10-Q filing

ReShape Lifesciences Inc. announced delayed annual 10-K filing

Analysts Have Lowered Expectations For ReShape Lifesciences Inc. (NASDAQ:RSLS) After Its Latest Results

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Health Check: How Prudently Does ReShape Lifesciences (NASDAQ:RSLS) Use Debt?

Third quarter 2021 earnings released: US$1.48 loss per share (vs US$0.74 loss in 3Q 2020)

Does ReShape Lifesciences (NASDAQ:RSLS) Have A Healthy Balance Sheet?

Second quarter 2021 earnings released: US$0.47 loss per share (vs US$0.52 loss in 2Q 2020)

High number of new directors

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to US$12.00

ReShape Lifesciences Inc. (OTCPK:RSLS) completed the acquisition of Obalon Therapeutics, Inc. (NasdaqCM:OBLN) in a reverse merger transaction.

ReShape Lifesciences Inc. (OTCPK:RSLS) entered into an agreement to acquire Obalon Therapeutics, Inc. (NasdaqCM:OBLN).

ReShape Lifesciences Inc. to Report Q2, 2020 Results on Aug 13, 2020

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad